
IMMUNOLOGY



F O U R T H E D I T I O N

visit our website www.whfreeman.com/immunology

RICHARD A. GOLDSBY | THOMAS J. KINDT | BARBARA A. OSBORNE



CONTENTS

Icons Used in This Book ii About the Authors vi Preface xix	
PART I INTRODUCTION	1
1 Overview of the Immune System 3 Historical Perspective 3 Discovery of Humoral and Cellular Immunity 4 Early Theories of Immunity 6 Components of Immunity 6	
Innate (Nonspecific) Immunity 7 Anatomic Barriers 7 Physiologic Barriers 8 Phagocytic Barriers 8 Inflammatory Barriers 9 Collaboration Between Innate and Adaptive Immunity 10	
Adaptive (Specific) Immunity 10 Cells of the Immune System 11 B Lymphocytes 11 T Lymphocytes 11 Antigen-Presenting Cells 12 Functions of Humoral and Cell-Mediated Immune Responses 12 Recognition of Antigen by B and T Lymphocytes Generation of Lymphocyte Specificity and Diversity 14	14
Role of the Major Histocompatibility Complex 1 Processing and Presentation of Antigens 15 Clonal Selection of Lymphocytes 16	4

Cellular Interactions Required for Generation

. Activation and Proliferation of T Helper Cells Generation of the Humoral Immune Response

Generation of the Cell-Mediated Response

18

of Immune Responses

Comparative Immunity 20
mmune Dysfunction and Its Consequences 21
Clinical Focus: Allergy and Asthma as Serious Public Health Problems 22
Summary 23 References/Study Questions 24
Cells and Organs of the ImmuneSystem 27
Hematopoiesis 27 Hematopoietic Growth Factors 29 Genes That Regulate Hematopoiesis 30 Regulation of Hematopoies s 30 Programmed Cell Death 31 Enrichment of Hematopoietic Stem Cells 34
Cells of the Immune System 35 Tyniphoid Cells 35
Clinical Focus: Clinical Uses of Hematopoletic Stem Cells 37
B Lymphocytes 39 T Lymphocytes 40 Null cells 41
Mononuclear Cells 41 Phagocytosis 42 Antimicrobial and Cytotoxic Activities 43 Antigen Processing and Presentation 44 Secretion of Factors 44
Granulocytic Celis 44 Neutrophils 44 Fosinophils 45 Basophils 45
Mast Cel s 45 Dendritic Cells 46
Organs of the Immune System 47

Primary Lymphoid Organs

50

Thymus 48

Bone Marrow

Lymphatic System 50 Secondary Lymphoid Organs 51 Lymph Nodes 51 Spleen 53 Mucosal-Associated Lymphoid Tissue 53 Cutaneous-Associated Lymphoid Tissue 57 Summary 57 References/Study Questions 57	Hinge Region 94 Other Constant-Region Domains 94 Immunoglobulin Classes and Biological Activities 95 Immunoglobulin-Mediated Effector Functions 95 Oponization 95 Activation of Complement 96 Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) 96
PART II GENERATION OF B-CELL AND T-CELL RESPONSES 61 3 Antigens 63 Immunogenicity Versus Antigenicity 63	Clinical Focus: Passive Antibody Therapy 98 Immunoglobulin G (IgG) 98 Immunoglobulin M (IgM) 99 Immunoglobulin A (IgA) 100 Immunoglobulin E (IgE) 101 Immunoglobulin D (IgD) 102
Factors That Influence Immunogenicity 63 Contribution of the Immunogen to Immunogenicity 64 Foreignness 64 Molecular Size 64 Chemical Composition and Heterogeneity 64 Susceptibility to Antigen Processing and Presentation 64 Contribution of the Biological System to Immunogenicity 65 Genotype of the Recipient Animal 66 Immunogen Dosage and Route of Administration 66 Adjuvants 66 Epitopes 67 Properties of B-Cell Epitopes 67 Properties of T-Cell Epitopes 73 Haptens and the Study of Antigenicity 76	Isotype 102 Allotype 102 Idiotype 103 B-Cell Receptor 103 The Immunoglobulin Superfamily 104 Monoclonal Antibodies 104 Formation and Selection of Hybrid Cells 106 Production of Monoclonal Antibodies 107 Clinical Uses for Monoclonal Antibodies 109 Catalytic Monoclonal Antibodies (Abzymes) 109 Summary 110 References/Study Questions 111
Clinical Focus: Drug Allergies—When Medicines Become Immunogens 78 Summary 78 References/Study Questions 80 4 Immunoglobulins: Structure and Function 83 Basic Structure of Immunoglobulins 83 Basic Structure of Antibody Molecules 84 Deducing Antibody Structure 85 Immunoglobulin Sequencing Studies 86 Role of Multiple Myeloma 86 Light-Chain Sequencing 86 Heavy-Chain Sequencing 86	5 Organization and Expression of Immunoglobulin Genes 115 Genetic Model Compatible with Ig Structure 116 Germ-Line and Somatic-Variation Models 116 The Two-Gene Model of Dryer and Bennett 117 Verification of the Dryer and Bennett Hypothesis 117 Multigene Organization of Ig Genes 118 λ-Chain Multigene Family 119 κ-Chain Multigene Family 120 Heavy-Chain Multigene Family 120 Variable-Region Gene Rearrangements 120 V-J Rearrangements in Light-Chain DNA 120 V-D-J Rearrangements in Heavy-Chain DNA 121
Immunoglobulin Fine Structure 87 Immunoglobulin Domains 87 Variable-Region Domains 89 CDRs and Antigen Binding 89 Conformational Changes Induced by Antigen Binding 92 Constant-Region Domains 93 CH1 and CL Domains 93	Mechanism of Variable-Region DNARearrangements122Recombination Signal Sequences122Enzymatic Joining of Gene Segments123Experimental Identification of Rag-1 and Rag-2 Genes124Defects in Ig-Gene Rearrangements125

Productive and Nonproductive Rearrangements 126 Allelic Exclusion 127	Radioimmunoassay 159
Generation of Antibody Diversity 128 Multiple Germ-Line V, D, and J Gene Segments 128 Combinatorial V-J and V-D-J Joining 128 Junctional Flexibility 129 P-Addition 130 N-Addition 130 Somatic Hypermutation 131 Association of Heavy and Light Chains 132	Indirect ELISA 161 Sandwich ELISA 161 Competitive ELISA 161 Chemiluminescence 161 ELISPOT Assay 162 Western Blotting 163 Immunoprecipitation 164
Class Switching Among Constant-Region Genes 132	Immunofluorescence 165
Expression of Ig Genes 133	
Differential RNA Processing of Heavy-Chain Primary Transcripts 135 Expression of Membrane or Secreted Immunoglobulin 135	Flow Cytometry and Fluorescence 166 Clinical Focus: Flow Cytometry and Leukemia Typing 168
Simultaneous Expression of IgM and IgD 13.5 Synthesis, Assembly, and Secretion of Immunoglobulins 136	Immunoelectron Microscopy 169 Summary 170 References/Study Questions 171
Regulation of Ig-Gene Transcription 136 Effect of DNA Rearrangement on Transcription 138 Inhibition of Ig-Gene Expression in T Cells 138	7 Major HistocompatibilityComplex 173
Antibody Genes and Antibody Engineering 138 Chimeric and Hybrid Monoclonal Antibodies 139 Monoclonal Antibodies Constructed from Ig-Gene Libraries 140 Clinical Focus: Therapy for Non-Hodgkin's	General Organization and Inheritance of the MHC 173 Location and Function of MHC Regions 173 MHC Haplotypes 175 Congenic MHC Mouse Strains 177
Lymphoma by a Genetically Engineered Antibody 141	MHC Molecules and Genes 178 Structure of Class I Molecules 178 Structure of Class II Molecules 180
Mice with Human Instead of Mouse Immunoglobulin Loci 144 Summary 144 References/Study Questions 145	Organization of Class I and II Genes 180 Peptide Binding by MHC Molecules 181 Class I MHC-Peptide Interaction 183 Class II MHC-Peptide Interaction 185
6 Antigen-Antibody Interactions 149 Strength of Antigen-Antibody Interactions 149	Polymorphism of Class I and Class II Molecules 186 Linkage Disequilibrium 186 Functional Relevance of MHC Polymorphism 187 Class III Molecules 188
Antibody Affinity 149 Antibody Avidity 152 Cross-Reactivity 153	Detailed Genomic Map of MHC Genes 188 Map of Class I MHC 188 Map of Class II MHC 190
•	Map of Class III MHC 190
Precipitation Reactions 153 Precipitation Reactions in Fluids 154 Precipitation Reactions in Gels 154 Radial Immunodiffusion (Mancini Method) 155 Double Immunodiffusion (Ouchterlony Method) 155 Immunoelectrophoresis 136	Cellular Distribution of MHC Molecules 190 Regulation of MHC Expression 191 MHC and Immune Responsiveness 192 MHC and Disease Susceptibility 193
Agglutination Reactions 157 Hemagglutination 158 Bacterial Agglutination 158	MHC and Disease Susceptibility 193 Clinical Focus: HLA-H and Hereditary Hemochromatosis 194
Passive Agglutination 158 Agglutination 158	Summary 196 References/Study Questions 197

8 Antigen Processing and Presentation 201	Affinity of TCR for Peptide-MHC Complexes 230
Self-MHC Restriction of T Cells 201	Ternary TCR-Peptide-MHC Complex 232
Role of Antigen-Presenting Cells 203 Early Evidence for the Necessity of Antigen Processing 203 Cells That Function in Antigen Presentation 204	Preparation of the TCR-Peptide-MHC Ternary Complex 232 A Three-Dimensional Structure of the TCR-Peptide-MHC Ternary Complex 232 Alloreactivity of T Cells 234
Evidence for Two Processing and Presentation	Summary 235
Pathways 204	References/Study Questions 236
Endogenous Antigens: The Cytosolic Pathway 206 Peptide Generation by Proteasomes 202 Peptide Transport from the Cytosol to the Rough	10 T-Cell Maturation, Activation, and Differentiation 239 T-Cell Maturation and the Thymus 239
Endoplasmic Reticulum (RER) 207 Assembly of Peptides with Class I MHC Molecules 208 Overview of Class I Endogenous Pathway 208	Thymic Selection of the T-Cell Repertoire Positive Selection 243 Negative Selection 244 Experimental Evidence for Positive Selection 244
Exogenous Antigens: The Endocytic Pathway 209 Peptide Generation in Endocytic Vesicles 209	Experimental Evidence for Negative Selection 246 Some Central Issues in Thymic Selection 246
Transport of Class II MHC Molecules to Endocytic Vesicles 210 Assembly of Peptides with Class II MHC Molecules 210 Overview of the Class II Exogenous Pathway 211	T _H -Cell Activation 249 Some Common Themes in Signal Transduction 250 TCR-Coupled Signaling Pathways 250 The Co-Stimulatory Signal 254 Clonal Expansion Versus Clonal Anergy 255
Presentation of Nonpeptide Bacterial	Superantigen-Induced T-Cell Activation 256
Antigens 212 Summary 213 References/Study Questions 213	T-Cell Differentiation 258 Generation of Effector and Memory T Cells 258 Co-Stimulatory Differences Among Antigen-Presenting Cells 259
9 T-Cell Receptor 215	Cell Death and T-Cell Populations 260
Early Studies of the T-Cell Receptor 215 Self-MHC Restriction of the T-Cell Receptor 216 Isolation of T-Cell Receptors 217	Peripheral γδ T Cells 261 Distribution of γδ T Cells 261 Ligands Recognized by γδ T Cells 261
Structure of T-Cell Receptors 217	Function of γδ T Cells 261
Organization and Rearrangement of TCR Genes 218	Clinical Focus: Failure of Apoptosis Causes Defective Lymphocyte Homeostatis 262
Identifying and Cloning the TCR Genes 218 TCR Multigene Families 219 Variable-Region Gene Rearrangements 220 Mechanism of TCR DNA Rearrangements 220	Summary 264 References/Study Questions 265 11 B-Cell Generation, Activation, and
Clinical Focus: T-Cell Rearrangements	Differentiation 269
as Markers for Cancerous Cells 222 Allelic Exclusion of TCR Genes 223 Structure of Rearranged TCR Genes 224 Generation of TCR Diversity 225	B-Cell Maturation 269 Bone Marrow Environment 270 Ig-Gene Rearrangements 270 Pre-B-Cell Receptor 272
T-Cell Receptor Complex: TCR-CD3 226	Transcription-Factor Activity 273
T-Cell Accessory Membrane Molecules 228 CD4 and CD8 Coreceptors 228	Cell-Surface Markers 273 B-1 and B-2 β Cells 273 Selection of Immature Serf-Reactive B Cells 273

Negative Selection 274 Rescue by Editing of Light-Chain Genes 275	Subfamilies of Class I Cytokine Receptors 312 IL-2 Receptor 314
Cell Activation and Proliferation 275 Thymus-Dependent and Thymus-Independent Antigens 275	Signal Transduction Mediated by Cytokine Receptors 315
	Cytokine Antagonists 318
Origin of Activating Signals 276 Transduction of Activating Signals 276 B-Cell-Coreceptor Complex 278	Cytokine Secretion by T _H 1 and T _H 2 Subsets Development of T _H 1 and T _H 2 Subsets Cytokine Cross-Regulation 321
Clinical Focus: X-Linked Agammaglobulinemia: A Failure in Signal Transduction and B-Cell Development 280	Role of T _H 1/T _H 2 Barance in Determining Disease Outcomes 322
Role of T _H Cells in Humoral Responses 281 Formation of T-B Conjugate 281 Contact-Dependent Help Mediated by CD40/CD40i Interaction 282 Signals Provided by T _H -Cell Cytokines 283 Negative Selection of Mature Self-Reactive B	Cytokine-Related Diseases 322 Bacterial Septic Shock 322 Bacterial Toxic Shock and Similar Diseases 323 Lymphoid and Myeloid Cancers 323 Chagas' Disease 323
Cells 284	Therapeutic Uses of Cytokines and Their Receptors 323
The Humoral Response 286 Primary and Secondary Responses 287	Clinical Focus: Therapy with Interferons 324
The Humoral Response to Hapten-Carrier Conjugates and	Summary 326
the Role of Helper T Cel's 288	References/Study Questions 326
In Vivo Sites for Induction of Humoral	, .
Response 289	13 The Complement System 329
Germinal Centers and Antigen-Induced B-Cell	The Functions of Complement 329
Differentiation 292	The Complement Components 330
Affinity Maturation 292 The Role of Somatic Hypermutation 292 The Role of Selection 294 Class Switching 294 Generation of Plasma Cells and Memory B Cells 295	Complement Activation 330 Classical Pathway 330 Alternative Pathway 335 The Lectin Pathway 337 Terminal Sequence: Formation of Membrane-Attack Complex 337
Regulation of B-Cell Development 296	Regulation of the Complement System 338
Regulation of the Immune Effector Response 296 Antigen-Mediated Regulation 297 Antibody-Mediated Suppression 297 Summary 297 References/Study Questions 298	Biological Consequences of Complement Activation 342 Cell Lysis 342 Inflammatory Response 345 Opsonization of Antigen 345 Viral Neutralization 345 Solubilization of Immune Complexes 346
PART III IMMUNE EFFECTOR MECHANISMS 301	Complement Deficiencies 347 Clinical Observations 347 Experimental Studies 348
12 Cytokines 303	Experimental Studies 348 Summary 348 References/Study Questions 349
Properties of Cytokines 303 General Structure of Cytokines 306 Function of Cytokines 306	14 Cell-Mediated Effector Responses 351 Effector Responses 351
Cytokine, Receptors 310 General Structure of Cytokine Receptors 310	General Properties of Effector T Cells 352

Activation Requirements 352 Cell-Adhesion Molecules 352 Effector Molecules 353	The Inflammatory Process 383 Central Role of Neutrophils in Inflammation 383 Acute Inflammatory Response 384
Cytotoxic T Cells 353 Generation of CTLs 353 Destruction of Target Cells by CTLs 354	Localized Response 384 Systemic Acute-Phase Response 384 Chronic Inflammatory Response 386 Role of IFN-γ and TNF-α 388
Natural Killer Cells 360 NK-Cell Lineage 360 Mechanism of NK-Cell Killing 360	Clinical Focus: Leukocyte-Adhesion Deficiency (LAD) in Humans and Cattle 387 Chronic Inflammatory Diseases 390
NK-Cell Receptors 36:	Anti-Inflammatory Agents 390
Antibody-Dependent Cell-Mediated Cytotoxicity	Agents That Reduce Leukocyte Extravasation 390
Experimental Assessment of Cell-Mediated Cytotoxicity 363 Mixed-Lymphocyte Reaction (MLR) 363 Cell-Mediated Lympholysis (CML) 364 Graft-Versus-Host Reaction 364	Corticosteroids 390 Nonsteroidal Anti-Inflammatory Drugs 391 Summary 391 References/Study Questions 392
Delayed-Type Hypersensitivity 365	
Phases of the DTH Response 365	16 Hypersensitive Reactions 395
Cytokines Involved in the DTH Reaction 366 Protective Role of the DTH Response 367	Gell and Coombs Classification 396
Detection of the DTH Reaction 368 Pathologic DTH Responses 368 Summary 368 References/Study Questions 369	IgE-Mediated (Type I) Hypersensitivity 397 Components of Type I Reactions 397 Allergens 397 Reaginic Antibody (IgE) 398 Mast Cells and Basophils 399 IgE-Binding Fc Receptors 399
15 Leukocyte Migration and Inflammation 371	lgE-Binding Fc Receptors 399 Mechanism of IgE-Mediated Degranulation 401 Receptor Crosslinkage 401 Intracellular Events Leading to Mast-Cell Degranulation 402
Lymphocyte Recirculation 371	Mediators of Type I Reactions 403
Cell-Adhesion Molecules 371 Selectin Family 372 Mucin-Like Family 372 Integrin Family 372 Immunoglobulin Superfamily 373	Histamine 403 Leukotrienes and Prostaglandins 404 Cytokines 404 Consequences of Type I Reactions 405 Systemic Anaphylaxis 405 Localized Anaphylaxis (Atopy) 405
Neutrophil Extravasation 373	Late-Phase Reaction 407
Lymphocyte Extravasation 374 High-Endothelial Venules 375 Homing of Lymphocytes 376 Naive Lymphocytes 377	Regulation of the Type I Response 407 Clinical Focus: The Genetics of Asthma 408 Detection of Type I Hypersensitivity 409
Effector and Memory Lymphocytes 378	Therapy for Type I Hypersensitivities 410
Adhesion-Molecute Interactions 378 .	Antibody-Mediated Cytotoxic (Type II)
Mediators of Inflammation Chemokines 379 Plasma Enzyme Mediators 380 Kinin System 380 Clotting System 381 Fibrinolytic System 382	Hypersensitivity 412 Transfusion Reactions 412 Hemolytic Disease of the Newborn 414 Drug-Induced Hemolytic Anemia 415 Immune Complex—Mediated (Type III)
Complement System 382 Lipid Inflammatory Mediators 382	Hypersensitivity 415
Cytokine Inflammatory Mediators 383	Localized Type III Reactions 416

Generalized Type III Reactions 417	Whole-Organism Vaccines 455
T _{DTH} -Mediated (Type IV) Hypersensitivity 417	Attenuated Viral or Bacterial Vaccines 455
Summary 419	Inactivated Viral or Bacterial Vaccines 457
References/Study Questions 419	Purified Macromolecules as Vaccines 457 Polysaccharide Vaccines 457
	Clinical Focus: Engineering a Live Virus Vaccine for Infant Diarrhea 458
PART IV THE IMMUNE SYSTEM	Toxoid Vaccines 458 Recombinant Antigen Vaccines 459
IN HEALTH AND DISEASE 423	Recombinant-Vector Vaccines 460
	DNA Vaccines 460
17 Immune Response to Infectious Diseases 425	Synthetic Peptide Vaccines 461
Viral Infections 426 Viral Neutralization by Humoral Antibody 427	Multivalent Subunit Vaccines 463 Summary 464
Cell-Mediated Antiviral Mechanisms 427 Viral Evasion of Host-Defense Mechanisms 428 Influenza 428	References/Study Questions 464
Properties of the Influenza Virus 428	19 AIDS and Other
Host Response to Influenza Infection 431	Immunodeficiencies 467
Bacterial Infections 432	Primary Immunodeficiencies 467
Immune Response to Extracellular and Intracellular	Defects in the Lymphoid Lineage 470
Bacteria 432	Severe Combined Immunodeficiency Disease (SCID) 470
Bacterial Evasion of Host Defense Mechanisms 432	Wiskott-Aldrich Syndrome (WAS) 472 Interferon-Gamma–Receptor Defect 472
Contribution of the Immune Response to Bacterial Pathogenesis 435	X-Linked Agammaglobulinemia 472
Diptheria (Corynebacterium diphtheriae) 435	X-Linked Hyper-IgM Syndrome 472 Common Variable Immunodeficiency (CVI) 473
Tuberculosis (Mycobacterium tuberculosis) 436	Common Variable Immunodeficiency (CVI) 473 Selective Deficiencies of Immunoglobulin Classes 473
Lyme Disease (Borrelia burgdorferi) 437	Ataxia Telangiectasia 473
Protozoan Diseases 438	Immune Disorders Involving the Thymus 473
Malaria (<i>Plasmodium</i> Species) 438	Defects in the Myeloid Lineage 474 Reduction in Neutrophil Count 474
Plasmodium Life Cycle and Pathogenesis of Malaria 438	Chronic Granulomatous Disease (CGD) 474
Host Response to Plasmodium Infection 439	Chediak-Higashi Syndrome 475
Design of Malaria Vaccines 440	Leukocyte-Adhesion Deficiency (LAD) 475
African Sleeping Sickness (<i>Trypanosoma</i> Species) 440 Leishmaniasis 440	Defects in the Complement System 476 Treatment of Immunodeficiency 476
•	Animal Models of Primary Immunodeficiency 476
Diseases Caused by Parasitic Worms	Nude (Athymic) Mice 477
(Helminths) 442	The SCID Mouse 477
Emerging Infectious Diseases 444	AIDS and Other Acquired or Secondary
Summary 446	Immunodeficiencies 478
References/Study Questions 446	The AIDS Epidemic 478
	Transmission of HIV-1 480 HIV-1: The AIDS Virus 480
	FIIV-1: The AIDS Virus 480 In Vitro Studies of the AIDS Virus 482
18 Vaccines 449	Clinical and Immunologic Consequences of HIV-1
	Infection 485
Active and Passive Immunization 450 Passive Immunization 450	Therapeutic Agents to Combat AIDS 489
Active Immunization 45!	Vaccines to Prevent AIDS 491
· ·	Summary 493
Designing Vaccines for Active Immunization 454	References/Study Questions 494

Disease Mediated by Direct Cellular Disease 198 Disease Mediated by Direct Cellular Demage 498 Ashimoso 199 Ashimoso 1	20 Autoimmunity 497	Role of Cell-Mediated Responses 519
Disease Mediated by Direct Cellular Damage 498 Hashimotos Throaditis 499 Goodpasture's Syndrome 499 Insulin-Dependent Dibases Meritius 499 Obisease Mediated by Stimutating or Blocking Auto-Ambrodies 500 Graves' Disease 500 Myashenia Clavis 501 Systemic Lupus Erythematosus 501 Myashenia Clavis 502 Scleroderma 503 Spottanegus Autoimmune Diseases 501 Systemic Autoimmune Diseases 501 Systemic Iupus Erythematosus 501 Mutility Escheros 502 Rhermatoid Arthritis 502 Scleroderma 503 Sportanegus Autoimmunity in Animals 503 Experimentally Induced Autoimmunity in Animals 504 Evidence Implicating the CD4* T Cell, MHC, and TCR in Autoimmunity 506 Release of Sequestered Antigens Association with the T-Ceil Receptor 506 Proposed Mechanisms for Induction of Autoimmunity 506 Release of Sequestered Antigens Minicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 T-Cell Vaccination 513 Poptide Biochade of MHC Molecules 513 About Collar Miniter 507 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 T-Cell Vaccination 513 Tolerance Induction 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Tolerance Induction 514 Treatment of Autoimmune 515 Tolerance Induction 515 Treatment of Autoimmune 515 Tolerance Induction 515 Treatment of Autoimmune 515 Tolerance Induction 511 Treatment of Autoimmune 515 T	Organ-Specific Autoimmune Diseases 498	•
### Sensitization Stage 521 Autoimmune Anemia 499 Insulin-Dependent Diabetee Meltins 499 Insulin-Dependent Diabetee Meltins 499 Diseases Mediated by Stimutating or Blocking Auto-Antifocities 500 Career Disease 500 Autoimmune Diseases 501 Systemic Lupus Erythematosus 501 Multiple Sciences 502 Rheumatoid Arthritis 502 Sciencedema 503 Spontaneous Autoimmune Disease 503 Spontaneous Autoimmune Disease 503 Spontaneous Autoimmunity in Animals 503 Experimentally Induced Autoimmunity 1 Animals 504 Exidence Implicating the CD4* T Cell, MHC, and TCR in Autoimmunity 505 Role of CD4* T Cells and FL/Tr _{II} /2 Balance 505 Association with the T-Cell Receptor 506 Release of Sequestred Antigens 506 Minicry Bevelon 827 Clinical Transplantation 530 Ridner Transplantation 530 Singerimentally Induced Autoimmunity 506 Release of Sequestred Antigens 508 Minicry Bransplantation 532 Liver Transplantation 532 Liver Transplantation 532 Liver Transplantation 533 Transplants to Immunology 539 Malignant Transformation of Cells 540 Oncogenes and Cancer Induction 541 Fencition of Cancer: A Multistrep Process 541 Inhibition of Cellular Publication 541 Fencition of Cancer: A Multistrep Process		
Autominine Anemias 499 Coordisauré Syndrome 499 Insulin-Dependent Diabetes Mellitus 499 Diseases Meditated by Stimutating or Blocking Auto-Antibodies 500 Graves Diseases 500 Mystiblema Gravis 501 Systemic Lupus Erythematosus 501 Systemic Lupus Erythematosus 501 Multiple Scleros 8 502 Rheumatoid Arthritis 502 Scleroderma 503 Animal Models for Autoimmune Diseases 503 Spontaneous Autoimmunity in Animals 503 Experimentally Induced Autoimmunity in Animals 503 Experimentally Induced Autoimmunity in Animals 504 Evidence Implicating the CD4* T Cell, MHC, and 1CR in Autoimmunity 505 Role of CD4* T Cells and T,1/T,1/2 Balance Association with the MHC 506 Association with the MHC 506 Association with the MHC 506 Molecular Mimicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity/ Gender Differences in Autoimmunity Gender Differences in Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 T-Cell Vaccination 513 Peptide Blockade of AHC Molecules 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Tolerance induction by Craft Rejection 518 Soundary 144 References/Study Questions 515 Tolerance induction 517 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Tolerance induction by Craft Analgens 514 Summary 514 References/Study Questions 515 Tolerance induction by Craft Analgens 514 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 546 Oncoderal Tumor Antigens 540 Oncoderal Tumor Antigen	G.,	Mechanisms Involved in Graft Rejection 521
Cinical Manifestations of Graft Rejection 524 Diseases Mediated by Stimutating or Blocking Auto-Antibodies 500 Graves Disease 500 Mysstemia Gravis 501 Mysstemia Lupus Erythematosus 501 Mysstemia Lupus Erythematosus 501 Multiple Scleros 5 502 Scleroderma 503 Spotaneous Autoimmune Disease 503 Spotaneous Autoimmune Disease 503 Spotaneous Autoimmunity in Animals 503 Experimentally Induced Autoimmunity in Animals 503 Experimentally Induced Autoimmunity 505 Role of CD4 * T Cells and T 1,171,2 Balance 505 Association with the M+C 506 Association with the T-Ccil Receptor 506 Proposed Mechanisms for Induction of Autoimmunity 506 Molecular Minicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity 506 Molecular Minicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity 506 Molecular Minicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity 506 Molecular Minicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity 506 Molecular Minicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity 506 Molecular Minicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity 506 Molecular Minicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity 506 Molecular Minicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity 506 Molecular Minicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity 506 Molecular Minicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity 506 Molecular Minicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity 506 Molecular Minicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity 506 Molecular Minicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity 506 Molecular Minicry 507 Clinical Focus Why Are Women More Susceptible Than Men to Autoimmunity 506 Molecular Minicry 507 Clinical Focus Why Are W		
Diseases Mediated by Stimulating or Blocking Auto-Antihodies 500 Graver Diseases 500 Ayushema Gravis 501 Systemic Lutoimmune Diseases 501 Multiple Scieros s 502 Remarked Arthritis 502 Scleroderm 503 Animal Models for Autoimmune Diseases 503 Spontaneous Autoimmune Diseases 503 Spontaneous Autoimmunity in Animals 503 Experimentally Induced Autoimmunity in Animals 503 Experimentally Induced Autoimmunity in Animals 503 Reperimentally Induced Autoimmunity 505 Role of CD4 * T Cells and T, I/T, I/Z Balance 505 Association with the T-Cell Receptor 506 Association with the MHC 506 Association with the T-Cell Receptor 506 Mol'ecular Minicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity 506 Mol'ecular Minicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity 506 Mol'ecular Minicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity 506 Mol'ecular Minicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity 506 Mol'ecular Minicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity 506 Mol'ecular Minicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity 506 Mol'ecular Minicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity 506 Mol'ecular Minicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity 506 Mol'ecular Minicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity 506 Mol'ecular Minicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity 506 Mol'ecular Minicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity 506 Mol'ecular Minicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity 506 Mol'ecular Minicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity 606 Mol'ecular Minicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmunity 606 Mol'ecular Minicry 507 Clinical Focus Wh		
Acute Rejection 526 Chronic Rejection 528 Conticulation 528 Control S27 Corticosterolds 527 Corticostero		
Chronic Rejection 526 Chronical Antibody Everapy 528 Monoclonal Antibody Inspection 530 Clinical Transplantation 530 Clinical Transplantation 530 Clinical Transplantation 532 Liver Transplantation 532 Liver Transplantation 532 Liver Transplantation 532 Liver Transplantation 533 Chronic Rejection 533 Chronic Rejection 532 Clinical Transplantation 532 Li	Diseases Mediated by Stimulating or Blocking	
Systemic Autoimmune Diseases 501 Systemic Lupus Erythematosus 501 Multiple Scleros's 502 Rheumatoid Arthritis 502 Scleroderma 503 Animal Models for Autoimmune Disease Spontaneous Autoimmunity in Animals 503 Experimentally Induced Autoimmunity in Animals 503 Experimentally Induced Autoimmunity 505 Role of CD4* T Cells, MHC, and TCR in Autoimmunity 505 Role of CD4* T Cells and T.1/T.1/2 Balance 505 Association with the MHC 506 Association with the MHC 506 Association with the MHC 506 Release of Sequestered Antigens 506 Release of Sequestered Antigens 506 Release of Sequestered Antigens 506 Molecular Mimilerry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity? Cender Differences in Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Pelyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Experimental Therapeutic Approaches 513 F-Cell Vaccination 513 Feptide Blockade of MHC Molecules 513 Follocation by Oral Antigens 514 References/Study Questions 515 Summary 514 References/Study Questions 515 Timmunologic Basis of Graft Rejection 518 Specific Limmunosuppressive Therapy 526 Altiotic Inhibitors 527 Cyclosoorin A, FK506, and Rapamycin 527 Total Lymphoid Irradiation 528 Specific Limmunosuppressive Therapy 528 Minorclonal Antibody treating 528 Monoclonal Antibody treating 530 Richery Transplantation 530 Richery Transplantation 532 Liver Transplantation 532 Liver Transplantation 532 Liver Transplantation 533 Transplants to Immunology 539 Malignant Transformation of Cells 540 Oncogenes and Cancer Induction 641 Induction of Caluar Proliferation 541 Influence o		
Systemic Autoimmune Diseases 501 Systemic Lupus Erythematosus 501 Multiple Scleros \$ 502 Rheumatoid Arthritis 502 Scleroderma 503 Animal Models for Autoimmune Disease 503 Spontaneous Autoimmunity in Animals 503 Experimentally Induced Autoimmunity in Animals 504 Evidence Implicating the CD4* T Cell, MHC, and TCR in Autoimmunity 505 Role of CD4* T Cells and T,1/T ₁₂ Balance 505 Association with the MHC 506 Mo'ecular Mimicry 507 Clinical Focus: Why Are Women More Succeptible Than Men to Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Peptide Bickclade of MHC Molecules 513 Polerance Induction by Oral Antigens 514 References/Study Questions 515 Timorrantinoingus 540 Mitotic inhibitors 527 Corticosteroids 527 Total Lymphoid Irradiation 528 Specific Immunosuppressive Therapy 528 Monoclonal Antibodies to T-Cell Components or Cytokines 528 Agents That Block the Co-Stimulatory Signal 529 Illinical Transplantation 530 Bone-Marrow Transplantation 530 Bone-Marrow Transplantation 530 Bone-Marrow Transplantation 532 Liver Transplantation 532 Liver Transplantation 533 Xenotransplantation 534 Xenotransplantation 535 Xenotransplantation 534 Xenotransplantation 535 Xenotransplantation 534 Xenotransplantation 534 Xenotransplantation 535 Xenotr		,
Systemic Lupus Erythematosus 501 Multiple Scleros's 502 Rheumatold Arthritis 502 Scleroderma 503 Spontaneous Autoimmunity in Animals 503 Spontaneous Autoimmunity in Animals 503 Spontaneous Autoimmunity in Animals 504 Evidence Implicating the CD4* T Cell, MHC, and TCR in Autoimmunity 505 Role of CD4* T Cells and T,1/T _{IL} B Balance 505 Association with the MHC 506 Association with the T-Cell Receptor 506 Proposed Mechanisms for Induction of Autoimmunity 506 Release of Sequestered Antigens 506 Molecular Mimicry 507 Clinical Focus: Why Are Women More Summary 534 References/Study Questions 513 Polycloral B-Cell Activation 511 Treatment of Autoimmune Disease 512 Current Therapiers 512 Experiment Perspectic Approaches 513 Polycloral B-Cell Activation 511 Treatment of Autoimmune Disease 512 Current Therapiers 512 Experiment Interspectic Approaches 513 Polycloral B-Cell Activation 511 Treatment of Autoimmune Disease 512 Current Therapiers 512 Experiment Interspectic Approaches 513 Polycloral B-Cell Activation 511 Treatment of Autoimmune Disease 512 Current Therapiers 512 Experiment Interspectic Approaches 513 Polycloral B-Cell Activation 511 Treatment of Autoimmune Disease 512 Current Therapiers 512 Experiment Interspectic Approaches 513 Polycloral B-Cell Activation 511 Treatment of Autoimmune Disease 512 Current Therapiers 512 Experiment Interspectic Approaches 513 Polycloral B-Cell Activation 511 Treatment of Autoimmune Disease 512 Current Therapiers 512 Experiment Interspectic Approaches 513 Polycloral B-Cell Activation 5		• • • • • • • • • • • • • • • • • • • •
Multiple Scleros's 502 Rheumatoid Arthritis 502 Scleroderma 503 Animal Models for Autoimmune Disease 503 Spontaneous Autoimmunity in Animals 503 Experimentally Induced Autoimmunity in Animals 503 Experimentally Induced Autoimmunity 503 Experimentally Induced Autoimmunity 505 Role of CD4* T Cells and T.,1/T.,1/2 Balance 505 Association with the MHC 506 Association with the T-Cell Receptor 506 Proposed Mechanisms for Induction of Autoimmunity 506 Release of Sequestered Antigens 506 Molecular Mimicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity Gender Differences in Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Ficell Vaccination 513 Peptide Blockade of MHC Molecules 513 Nonoclonal Antibody in Cells soft in MHC Molecules 511 Polyclonal Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Polerance Induction by Oral Antigens 514 Nonoclonal Antibody in Cells 540 Oncogene and Cancer Induction 541 Function of Cancer-Associated Genes 541 Induction of Cellular Proliferation 541 Regulation of Programmed Cell Death 542 Conversion of Proto-Oncogenes to Oncogenes 543 Induction of Cancer: A Multistep Process 544 Tumor Associated Artigens 545 Tumor Specific Antigens 545 Tumor Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 546 Oncogene Proteins as Tumor Antigens 549 Oncogene Treatment 549 Oncogene Treatment 549 Oncogene Proteins as Tumor Antigens 549 Oncogene Treatment 540	,	
Schematoid Arthritis 502 Scleroderma 503 Scheroderma 503 Spontaneous Autoimmune Disease 503 Spontaneous Autoimmunity in Animals 503 Experimentally Induced Autoimmunity in Animals 504 Evidence Implicating the CD4* T Cell, MHC, and TCR in Autoimmunity 505 Role of CD4* T Cells and T.,1/T.,2 Balance 505 Association with the MHC 506 Association with the MHC 506 Release of Sequestered Antigens 506 Release of Sequestered Antigens 506 Molecular Homitry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class il MHC Molecules 511 Polyclonal B-Cell Activation 513 Peptide Blockade of MHC Molecules 513 Amonoclonal-Antibody Treatment 513 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Amonoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 515 Summary 514 References/Study Questions 515 Summary 514 References/Study Questions 515 Timmon-Specific Antigens 544 Summary 514 References/Study Questions 545 Immor-Associated Antigens 540 Oncogene and Cancer Induction of Cellular Prolitication 541 Function of Cellular Prol		
Scleroderma 503 Animal Models for Autoimmune Disease 503 Spontaneous Autoimmunity in Animals 503 Experimentally Induced Autoimmunity in Animals 504 Evidence Implicating the CD4* T Cell, MHC, and TCR in Autoimmunity 505 Role of CD4* T Cells and T, I/T _{I/I} Balance 505 Association with the MHC 506 Association with the T-Cell Receptor 506 Association with the T-Cell Receptor 506 Association with the T-Cell Receptor 506 Mo'ecular Mimicry 507 Clinical Transplantation 532 Liver Transplantation 533 Evidence Implicating 533 Evidence Implicating 533 Evidence Implicating the CD4* T Cell, MHC, and TCR in Autoimmunity 506 Association with the MHC 506 Association with the T-Cell Receptor 506 Association with the T-Cell Receptor 506 Mo'ecular Mimicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity 507 Clinical Focus: Why Are Women More Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapeutic Approaches 513 Treatment of Autoimmune Diseases 512 Current Therapeutic Approaches 513 Tolerance Induction by Oral Antigens 514 References/Study Questions 515 Tumor-Specific Antigens 544 Tumors of the Immune System 544 Tumor Antigens 549 Oncogene Tumor Antigens 549 Oncogeneal Antigens 549 Oncogeneal Inmor Antigens 540 Oncogeneal Antigens 540 Oncogeneal Inmor Antigens 540	•	
Animal Models for Autoimmune Disease 503 Spontaneous Autoimmunity in Animals 503 Experimentally Induced Autoimmunity in Animals 504 Evidence Implicating the CD4* T Cell, MHC, and TCR in Autoimmunity 505 Role of CD4* T Cells and T., I.T., 2 Balance 505 Association with the HHC 506 Association with the T-Cell Receptor 506 Association with the T-Cell Receptor 506 Association with the HHC 506 Association with the T-Cell Receptor 506 Association with the HHC 506 Association with the MHC 506 Association with the T-Cell Receptor 506 Association with the MHC 506 Association with the T-Cell Receptor 506 Association with the MHC 506 Association with the T-Cell Receptor 506 Aleat Transplantation 532 Acnoral Transplantation 5		iotal Lymphoid Irradiation 528
Spontaneous Autoimmunity in Animals 503 Experimentally Induced Autoimmunity in Animals 504 Evidence Implicating the CD4* T Cell, MHC, and TCR in Autoimmunity 505 Role of CD4* T Cells and T.,1/T _{1/2} Balance 505 Association with the MHC 506 Association with the T-Cell Receptor 506 Proposed Mechanisms for Induction of Autoimmunity 506 Release of Sequestered Antigens 506 Mo'ecular Mimilcry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity' Gender Differences in Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Apenide Blockade of MHC Molecules 513 Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Immunologic Basis of Graft Rejection 518 Specificity and Memory of the Rejection 518 Specificity and Memory of the Rejection 518 Or Cytokines 528 Agents That Block the Co-Stimulatory Signal 529 Agents That Block the Co-Stimulatory Signal 529 Agents That Block the Co-Stimulatory Signal 529 Clinical Transplantation 530 Bone-Marrow Transplants 530 Heart Transplantation 532 Ling Transplantation 532 Ling Transplantation 532 Pancreas Transplantation 532 Fancreas Transplantation 533 Skin Grafting 533 Xenotransplantation 533 Transplants to Immunology 518 References/Study Questions 535 22 Cancer and the Immune System 539 Malignant Transformation of Cellular Proliferation 541 Inhibition of Cellular Proliferation 541 In		Specific Immunosuppressive Therapy 528
Experimentally Induced Autoimmunity in Animals 504 Fidence Implicating the CD4* T Cell, MHC, and TCR in Autoimmunity 505 Role of CD4* T Cells and T.,1/T. Balance 505 Association with the MHC 506 Association with the T-Cell Receptor 506 Froposed Mechanisms for Induction of Autoimmunity 507 Release of Sequestered Antigens 506 Release of Sequestered Antigens 506 Molecular Mirnicry 507 Clinical Transplantation 530 Heart Transplantation 532 Ling Transplantation 532 Ling Transplantation 532 Ling Transplantation 533 Heart Transplantation 533 Skin Grafting 533 Xenotransplantation 533 Xenotransplantation 533 Xenotransplantation 533 Transplantation 533 Transplants to Immunologically Privilegeo Sites 534 Summary 534 References/Study Questions 535 Summary 534 References/Study Questions 535 Alignant Transformation of Cells 540 Oncogenes and Cancer Induction 541 Function of Cancer-Associated Genes 541 Inhibition of Cellular Prohiteration 541 Reputation of Programmed Cell Death 542 Conversion of Proto-Oncogenes to Oncogenes 543 Induction of Cancer: A Multistep Process 544 Tumor Antigens 545 Tumor Antigens 546 Chemically or Physically Induced Tumor Antigens 546 Immunologic Basis of Graft Rejection 518 Specificity and Memory of the Rejection 518 Specificity and Memory of the Rejection 518		·
Clinical Transplantation 530	•	•
Evidence Implicating the CD4* T Cell, MHC, and TCR in Autoimmunity 505 Role of CD4* T Cells and T.41/Tij2 Balance 505 Association with the MHC 506 Association with the MHC 506 Release of Sequestered Antigens 506 Release of Sequestered Antigens 506 Mo'ecular Mimicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity? Gender Differences in Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Peptide Blockade of MHC Molecules 513 Monoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Immunologic Basis of Graft Rejection 518 Specificity and Memory of the Rejection 518 Specificity and Memory of the Rejection 518 Sidney Transplantation 530 Kidney Transplantation 530 Kidney Transplantation 530 Kidney Transplantation 530 Ridney Transplantation 532 Liver Transplantation 532 Liver Transplantation 32 Liver Transplantation 532 Liver Transplantation 541 References/Study Questions 515 Function of Celluar Prolife		Agents That Block the Co-Stimulatory Signal 529
Role of CD4* T Cells and T.1/T.1/2 Balance 505 Association with the MHC 506 Association with the MHC T.Cell Receptor 506 Association with the MHC T.Cell Receptor 506 Proposed Mechanisms for Induction of Autoimmunity 506 Release of Sequestered Antigens 506 Molecular Mimicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapeits Approaches 513 Peptide Blockade of MHC Molecules 513 Monoclonal-antibody Treatment 513 Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Tumor Antigens 545 Tumor-Specific Antigens 549 Oncogene Proteins as Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550	in Animals 504	Clinical Transplantation 530
Role of CD4 T Cells and T.1/TH2 Balance 505 Association with the MHC 506 Association with the MHC 506 Association with the T.Cell Receptor 506 Proposed Mechanisms for Induction of Autoimmunity 506 Release of Sequestered Antigens 506 Mo'ecular Mimicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Peptide Blockade of MHC Molecules 513 Polyclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 1 Immors of the Immune System 544 Tumor Antigens 545 Timor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 549 Oncogene Proteurs as Tumor Antigens 550	Evidence Implicating the CD4 ⁺ T Cell, MHC, and	Kidney Transplantation 530
Role of CD4* T Cells and T.,1/T _H 2 Balance Association with the MHC 506 Association with the MHC 506 Association with the T-Cell Receptor 506 Proposed Mechanisms for Induction of Autoimmunity 506 Release of Sequestered Antigens 506 Mo'ecular Mimicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Peptide Blockade of MHC Molecules 513 Tolerance Induction by Oral Antigens 514 References/Study Questions 545 Immunologic Basis of Graft Rejection 518 Specificity and Memory of the Rejection 518 Association with the T-Ceil Receptor 506 Lung Transplantation 532 Lung Transplantation 533 Xenotransplantation 533 Transplantation 533 Xenotransplantation 533 Xenotransplantation 534 Xenotransplantation 533 Xenotransplantation 533 Xenotransplantation 534 Xenotransplantation 532 Xeno	TCR in Autoimmunity 505	•
Association with the T-Ceil Receptor 506 Proposed Mechanisms for Induction of Autoimmunity 506 Release of Sequestered Antigens 506 Molecular Mimicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity? Gender Differences in Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Experimental Therapeutic Approaches 513 Teptide Blockade of MHC Molecules 513 Peptide Blockade of MHC Molecules 513 Peptide Blockade of MHC Molecules 513 Peptide Blockade of MHC Molecules 513 Nonoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 References/Study Questions 544 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 546 Virally Induced Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 549 Oncogene Tolerons as Tumor Antigens 549 Oncogene Tolerons 549 Oncogene Transplantation 533 Skin Graft Rejection 503 Skin Grafting 533 Skin Grafting 533 Skin Grafting 533 Xenotransplantation 533 Skin Grafting 533 Skin Grafting 533 Skin Grafting 533 Transplantation 533 Transplantation 535 Summary 534 References/Study Questions 535 **Cell Activation 535 **Cancer Origin and Terminology 539 **Malignant Transformation of Cellus Proliferation 541 Inhibition of Cellular Proliferation 541 Regulation of Prote-Oncogenes to Oncogenes 543 Induction of Cancer: A Multistep Process 544 **Tumor Antigens 545 **Tumor-Associated Antigens 546 Chemically or Physically Induced Tumor Antigens 546 Oncogene Proteins as Tumor Antigens 549 Oncofetal Tumor Antigens 549 Oncofetal Tumor Antigens 549 Oncofetal Tumor Antigens 550		•
Proposed Mechanisms for Induction of Autoimmunity 506 Release of Sequestered Antigens Mo'ecular Mimicry 507 Summary 534 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity? Gender Differences in Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 1512 Current Therapies 512 Experimental Therapeutic Approaches 1513 Regulation of Programmed Cell Death Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Tumor Antigens 540 Pancreas Transplantation 533 Skin Grafting 533 Xenotransplantation 973 Xenotransplantation munuclogically Privileged Sites 534 Autoransplantation Immune System 534 Numer Antigens 540 Oncogenes and Cancer and the Immune System 549 Oncogenes and Cancer Induction 541 Function of Cancer-Associated Genes 541 Influction of Calcular Proliferation 541 Regulation of Proto-Oncogenes to Oncogenes to Oncogenes to Oncogenes 543 Induction of Cancer: A Multisep Process 544 Tumor-Associated Antigens 549 Oncogene Frotens as Tumor Antigens 549 Oncogene Frotens as Tumor Antigens 549 Oncogene Proteins as Tumor Anti	Association with the MHC 506	• • •
Action of Autoimmunity 506 Release of Sequestered Antigens 506 Rolease of Sequestered Antigens 533 Renotransplantation 534 References/Study Questions 535 **Conner: Origin and Terminology 539 **Malignant Transformation of Cells 540 **Oncogenes and Cancer Induction 541 Regulation of Cancer-Associated Genes 541 Inhibition of Cellular Proliferation 541 Regulation of Proto-Oncogenes to Oncogenes 543 Induction of Cancer: A Multistep Process 544 **Immor Antigens 545 **Immor Antigens 546 **Openios and Terminology 541 **Immor Antigens 546 **Immor Antigens 546 **Openios and Terminology 541 **Immor Antigens 546 **Immor Antigens 546 **Openios and Terminology 541 **Immor Antigens 546 **Immor Antigens 546 **Openios and Terminology 541 **Immor Of Cellular Proliferation 541 **Immor Of Cellular Proliferation 541 **Immor Of Cellular Proliferation 541 **Immor Of Cellular Proliferation 541 **Immor Of Cellular Proliferation 541 **Immor Of Cellular Proli	Association with the T-Ce'l Receptor 506	
Autoimmunity 506 Release of Sequestered Antigens 506 Release of Sequestered Antigens 506 Mo'ecular Mimicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity? Gender Differences in Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Celi Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 T-Cell Vaccination 513 Peptide Blockade of MHC Molecules 513 Monoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Immunologic Basis of Graft Rejection 518 Specificity and Memory of the Rejection 518 Specificity and Memory of the Rejection 518 Socialist Autoimmune 533 Transplantation 533 Transplantation Immunology 517 Immunologic Basis of Graft Rejection 518 Summary 534 References/Study Questions 515 Xenotransplantation Immunologic Intermediation 533 Transplantation Immunologic Intermediation 533 Transplantation Immunologic Intermediation 533 Transplantation Immunologic Intermediation Immunologic Intermediation 533 Transplantation Immunology 549 Xenotransplantation Immunologic Intermediation Immunologic Intermediation Immunologic Intermediation Immunologic Intermediation Immunologic Intermediation Intermediation Immunology 517 Immunologic Basis of Graft Rejection 518 Specificity and Memory of the Rejection 518	Proposed Mechanisms for Induction	
Release of Sequestered Antigens 506 Mo'ecular Mimicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity? Gender Differences in Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Peptide Blockade of MHC Molecules 513 Peptide Blockade of MHC Molecules 513 Tolerance Induction by Oral Antigens 514 References/Study Questions 515 Tumor Antigens 545 Tumor Specific Antigens 546 Chemically or Physically induced Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 549 Summary 514 Transplants to Immunologically Privileged Sites 534 Summary 534 References/Study Questions 535 Summary 534 References/Study Questions 535 Transplants to Immunologically Privileged Sites 534 Summary 534 References/Study Questions 535 Summary 534 References/Study Questions 535 Cancer: Origin and Terminology 539 Malignant Transformation of Cells 540 Oncogenes and Cancer Induction 541 Function of Cancer-Associated Genes 541 Inhibition of Cellular Proliferation 541 Regulation of Prote-Oncogenes to Oncogenes 543 Induction of Cancer: A Multistep Process 544 Tumor-Specific Antigens 546 Chemically or Physically induced Tumor Antigens 546 Oncogene Proteins as Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550		**
Molecular Mimicry 507 Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity? Gender Differences in Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 T-Cell Vaccination 513 Peptide Blockade of MHC Molecules 513 Monoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Immunologic Basis of Graft Rejection 518 Specificity and Memory of the Rejection 518 Susceptible Than Men to Autoimmune References/Study Questions 535 References/Study Questions 535 Cancer: Origin and Terminology 539 Malignant Transformation of Cells 540 Oncogenes and Cancer Induction 541 Induction of Cancer-Associated Genes 541 Induction of Cellular Proliferation 541 Inhibition of Cellular Proliferation 541 Inhibition of Proto-Oncogenes to Oncogenes 543 Induction of Cancer: A Multistep Process 544 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically induced Tumor Antigens 546 Oncogene Proteins as Tumor Antigens 549	,	•
Clinical Focus: Why Are Women More Susceptible Than Men to Autoimmunity? Gender Differences in Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 T-Cell Vaccination 513 Peptide Blockade of MHC Molecules 513 Amonoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Tumor Antigens 545 Tumor Antigens 545 Tumor-Specific Antigens 549 Oncogene Proteins as Tumor Antigens 540	·	
Susceptible Than Men to Autoimmunity? Gender Differences in Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Peptide Blockade of MHC Molecules 513 Monoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Immunologic Basis of Graft Rejection 518 Specificity and Memory of the Rejection 518 Specificity and Memory of the Rejection 510 Cancer: Origin and Terminology 539 Malignant Transformation of Cells 540 Malignant Transformation of Cells 540 Oncogenes and Cancer Induction 541 Function of Cancer-Associated Genes 541 Inhibition of Cellular Proliferation 541 Regulation of Programmed Cell Death 542 Conversion of Proto-Oncogenes to Oncogenes 543 Induction of Cancer: A Multistep Process 544 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 546 Virally Induced Tumor Antigens 549 Oncoferal Tumor Antigens 549 Oncoferal Tumor Antigens 549 Oncoferal Tumor Antigens 559 Oncogene Proteins as Tumor Antigens 550	,	•
Gender Differences in Autoimmune Disease 508 Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Peptide Blockade of MHC Molecules 513 Peptide Blockade of MHC Molecules 513 Monoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Tumor Antigens 546 Chemically or Physically induced Tumor Antigens 548 Specificity and Memory of the Rejection 518 Specific type and the Immune System 549 Cancer: Origin and Terminology 539 Cancer: Origin and Terminology 539 Malignant Transformation of Cells 540 Oncogenes and Cancer Induction 541 Function of Cancer-Associated Genes 541 Inhibition of Cellular Proliferation 541 Inhibition of Cellular Proliferation 541 Inhibition of Cellular Proliferation 541 Function of Cancer-Associated Genes 541 Inhibition of Cellular Proliferation 541 Function of Cancer-Associated Genes 541 Inhibition of Cellular Proliferation 541 Function of Cancer-Associated Genes 541 Inhibition of Cellular Proliferation 541 Function of Cancer-Associated Genes 541 Inhibition of Cancer-Associated Genes 544 Inhibition of Cellular Prolifer		References/study Questions 333
Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Peptide Blockade of MHC Molecules 513 Peptide Blockade of MHC Molecules 513 Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 548 Tumor-Associated Antigens 549 Oncogene and Cancer Induction 541 Function of Cancer-Associated Genes 541 Induction of Cellular Proliferation 541 Regulation of Programmed Cell Death 542 Conversion of Proto-Oncogenes to Oncogenes 543 Induction of Cancer: A Multistep Process 544 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 546 Virally Induced Tumor Antigens 548 Tumor-Associated Antigens 549 Oncogene Proteins as Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 559		
Mimicry Between MBP and Viral Peptides 510 Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Peptide Blockade of MHC Molecules 513 Peptide Blockade of MHC Molecules 513 Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Immunologic Basis of Graft Rejection 518 Specificity and Memory of the Rejection 518 Specificity and Memory of the Rejection 518 Specificity and Memory of the Rejection 510 Malignant Transformation of Cells 540 Malignant Transformation of Cells 541 Function of Cellular Proliferation 541 Regulation of Proto-Oncogenes to Oncogenes 543 Induction of Cancer: A Multistep Process 544 Itumors of the Immune System 544 Tumor Antigens 545 Tumor Antigens 546 Chemically or Physically Induced Tumor Antigens 546 Virally Induced Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550		22 Cancer and the Immune System = 20
Inappropriate Expression of Class II MHC Molecules 511 Polyclonal B-Cell Activation 511 **Treatment of Autoimmune Diseases** 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Peptide Blockade of MHC Molecules 513 Peptide Blockade of MHC Molecules 513 Monoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 **References/Study Questions 515** **Tumor Antigens 546 Chemically or Physically Induced Tumor Antigens 548 **Tumor-Associated Antigens 549 Oncogene Proteins as Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550		,
Molecules 511 Polyclonal B-Cell Activation 511 Treatment of Autoimmune Diseases Current Therapies 512 Experimental Therapeutic Approaches 513 Peptide Blockade of MHC Molecules 700 Autoimmune 513 Peptide Blockade of MHC Molecules 513 Tolerance Induction by Oral Antigens 514 References/Study Questions 515 Tumor Antigens 545 Tumor Antigens 546 Chemically or Physically Induced Tumor Antigens 548 Tumor-Associated Antigens 549 Oncogene Proteins as Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550	•	
Treatment of Autoimmune Diseases 512 Current Therapies 512 Experimental Therapeutic Approaches 513 Peptide Blockade of MHC Molecules 513 Monoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 References/Study Questions 515 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 548 Tumor-Associated Genes 541 induction of Calcular Proliferation 541 Regulation of Proto-Oncogenes to Oncogenes 543 Induction of Cancer: A Multistep Process 544 Tumors of the Immune System 544 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 548 Tumor-Associated Antigens 549 Oncofetal Tumor Antigens 549 Oncofetal Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550		Malignant Transformation of Cells 540
Current Therapies 512 Experimental Therapeutic Approaches 513 Peptide Blockade of MHC Molecules 513 Monoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 References/Study Questions 515 Tumor Antigens 546 Chemically or Physically Induced Tumor Antigens 548 Tumor-Associated Antigens 549 Oncogene Proteins as Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550 Inhibition of Cellular Proliferation 541 Inhibition of Cellular Proliferation 541 Regulation of Programmed Cell Death 542 Conversion of Proto-Oncogenes to Oncogenes 543 Induction of Cancer: A Multistep Process 544 Tumors of the Immune System 544 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 548 Tumor-Associated Antigens 549 Oncogene Proteins as Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550	Polyclonal B-Cell Activation 511	•
Experimental Therapeutic Approaches 513 Experimental Therapeutic Approaches 513 Peptide Blockade of MHC Molecules 513 Monoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 References/Study Questions 515 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 548 Tumor-Associated Antigens 549 Oncoferal Tumor Antigens 549 Oncoferal Tumor Antigens 549 Oncoferal Tumor Antigens 549 Oncoferal Tumor Antigens 550	Treatment of Autoimmune Diseases 512	
Experimental Therapeutic Approaches 513 T-Cell Vaccination 513 Peptide Blockade of MHC Molecules 513 Monoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 548 Tumor-Associated Antigens 549 Oncoferal Tumor Antigens 549 Oncoferal Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550	Current Therapies 512	
T-Cell Vaccination 513 Peptide Blockade of MHC Molecules 513 Monoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 548 Tumor-Associated Antigens 549 Oncofetal Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550	Experimental Therapeutic Approaches 513	
Monoclonal-Antibody Treatment 513 Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 548 1 Transplantation Immunology 517 Immunologic Basis of Graft Rejection 518 Specificity and Memory of the Rejection 518 Concogene Proteins as Tumor Antigens 549 Concogene Proteins as Tumor Antigens 550		Conversion of Proto-Oncogenes to Oncogenes 543
Tolerance Induction by Oral Antigens 514 Summary 514 References/Study Questions 515 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 548 21 Transplantation Immunology 517 Immunologic Basis of Graft Rejection 518 Specificity and Memory of the Rejection 518 Oncoferal Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550		Induction of Cancer: A Multistep Process 544
References/Study Questions 515 Tumor Antigens 545 Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 546 Virally Induced Tumor Antigens 548 Tumor-Associated Antigens 549 Oncoferal Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550		Tumors of the Immune System 544
Tumor-Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 546 Virally Induced Tumor Antigens 548 Immunologic Basis of Graft Rejection Specificity and Memory of the Rejection Specificity and Memory of the Rejection Tumor-Specific Antigens 546 Virally Induced Tumor Antigens 549 Oncofetal Tumor-Associated Antigens 549 Oncofetal Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550	Summary 514	·
21 Transplantation Immunology 517 Immunologic Basis of Graft Rejection Specificity and Memory of the Rejection Specificity and Memory of the Rejection Specificity and Memory of the Rejection Specific Antigens 546 Chemically or Physically Induced Tumor Antigens 548 Tumor-Associated Antigens 549 Oncofetal Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550	References/Study Questions 515	-
21 Transplantation Immunology 517 Immunologic Basis of Graft Rejection Specificity and Memory of the Rejection		
Immunologic Basis of Graft Rejection 518 Specificity and Memory of the Rejection 518 Specificity and Memory of the Rejection 518 Tumor-Associated Antigens 549 Oncofetal Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550	21 Transplantation Immunology 517	
Specificity and Memory of the Rejection Oncofetal Tumor Antigens 549 Oncogene Proteins as Tumor Antigens 550	, ,	•
B	<u> </u>	Oncofetal Tumor Antigens 549
	Response 518	Oncogene Proteins as Tumor Antigens 550 TATAs on Human Melanomas 550

xvii

Role of NK Cells and Macrophages 551 Immune Surveillance Theory 551	Labeling Proteins with Biotin 571 Gel Electrophoresis 571 X-Ray Crystallography 573
Tumor Evasion of the Immune System 551 Immunologic Enhancement of Tumor Growth 551 Modulation of Tumor Antigens 552 Reduction in Class I MHC Molecules 552 Lack of Co-Stimulatory Signal 553	Recombinant DNA Technology 576 Restriction-Endonuclease Cieavage of DNA 576 Cloning of DNA Sequences 577 Cloning Vectors 577 Cloning of cDNA and Genomic DNA 577 Selection of DNA Clones 579
Cancer Immunotherapy 553 Manipulation of Co-Stimulatory Signa. 553 Enhancement of APC Activity 554	Southern Blotting 579 Northern Blotting 580 Polymerase Chain Reaction 580
Cytokine Therapy 554 Interferons 554 Tumor Necrosis Factors 554 In Vitro-Activated LAK and TIL Cells 555 Monoclonal Antibodies 556	Analysis of DNA Regulatory Sequences 580 DNA Footprinting 581 Gel-Shift Analysis 582 CAT Assay 582
Cancer Vaccines 558 Summary 559 References/Study Questions 560	Gene Transfer into Mammalian Cells 583 Transfer of Cloned Genes into Cultured Cells 583 Transfer of Cloned Genes into Mouse Embryos 584
23 Experimental Systems 563 Experimental Animal Models 563 Inbred Strains 563	Transgenic Mice 584 Gene-Targeted Knockout Mice 585 The "Knock-In" Technology 587 Inducible Gene Targeting—The Cre/lox System 588 Summary 589
Adoptive-Transfer Systems 564 The Hemolytic Plaque Assay 566 SCID Mice and SCID-Human Mice 567	References/Study Questions 590 Appendix: CD Antigens 593
Cell-Culture Systems 568	Appendix: CD Antigens 593
Primary Lymphoid Cell Cultures 568 Cloned Lymphoid Cell Lines 568 Hybrid Lymphoid Cell Lines 569	Glossary 609 Answers to Study Questions 625
Protein Biochemistry 570 Radiolabeling Techniques 571	Credits 643